MedKoo Cat#: 571494 | Name: KUN75125

Description:

WARNING: This product is for research use only, not for human or veterinary use.

KUN75125 is a phosphodiesterase-4 (PDE4) allosteric modulator with IC50 values of 8 and 130 nM against human and mouse PDE4D, respectivel. It may help reverse scopolamine-induced cognitive impairment.

Chemical Structure

KUN75125
KUN75125
CAS#1606975-12-5

Theoretical Analysis

MedKoo Cat#: 571494

Name: KUN75125

CAS#: 1606975-12-5

Chemical Formula: C19H14ClF3N4O

Exact Mass: 406.0808

Molecular Weight: 406.79

Elemental Analysis: C, 56.10; H, 3.47; Cl, 8.71; F, 14.01; N, 13.77; O, 3.93

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
KUN75125; KUN 75125; KUN-75125
IUPAC/Chemical Name
2-(4-((2-(3-chlorophenyl)-6-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acetamide
InChi Key
KRRGWHSEDYQKDQ-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H14ClF3N4O/c20-13-3-1-2-12(9-13)18-26-15(19(21,22)23)10-17(27-18)25-14-6-4-11(5-7-14)8-16(24)28/h1-7,9-10H,8H2,(H2,24,28)(H,25,26,27)
SMILES Code
O=C(N)CC1=CC=C(NC2=NC(C3=CC=CC(Cl)=C3)=NC(C(F)(F)F)=C2)C=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Novel phosphodiesterase inhibitors are being studied to treat Alzheimer’s disease. Phosphodiesterases (PDEs) hydrolyze cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). They are prominently expressed in the brain, and thus are targeted in Alzheimer’s disease treatments to regulate cAMP and cGMP concentrations (which can lead to a downstream control of various proteins involved in cognitive maintenance). PDE inhibitors have been shown to effect cognitive improvement in dealing with common dementia symptoms, including progressive memory loss, a decline in language skills, and some other neurodegenerative disorders, in comparison with the available treatments of acetylcholine inhibitors, which do not reverse the progression of Alzheimer’s.

Preparing Stock Solutions

The following data is based on the product molecular weight 406.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Gurney ME, Cogram P, Deacon RM, Rex C, Tranfaglia M. Multiple Behavior Phenotypes of the Fragile-X Syndrome Mouse Model Respond to Chronic Inhibition of Phosphodiesterase-4D (PDE4D). Sci Rep. 2017 Nov 7;7(1):14653. doi: 10.1038/s41598-017-15028-x. PubMed PMID: 29116166; PubMed Central PMCID: PMC5677090. 2: Prickaerts J, Heckman PRA, Blokland A. Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease. Expert Opin Investig Drugs. 2017 Sep;26(9):1033-1048. doi: 10.1080/13543784.2017.1364360. Epub 2017 Aug 9. Review. PubMed PMID: 28772081. 3: Wu Y, Li Z, Huang YY, Wu D, Luo HB. Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease. J Med Chem. 2018 Feb 5. doi: 10.1021/acs.jmedchem.7b01370. [Epub ahead of print] PubMed PMID: 29363967.